Live Chat

BioNTech live chart

Mga Pangunahing Kaalaman sa Instrumento

Weekly Search
Weekly
Daily
Petsa Isarado Pagbabago Change (%) Buksan High Low

Balita

Info

Spread

0.7902

Spread (%)

0.7099 %

Leverage

1:10

Interes sa Magdamagang Pagbili

-0.0597 %

Interes sa Magdamagang Pagtinda

-0.0292 %

Currency

USD

Trading Hours

Oras ng Pagsasara

Lunes

13:31 - 19:59

Martes

13:31-19:59

Miyerkules

13:31-19:59

Huwebes

13:31-19:59

Biyernes

13:31-19:59

Analys och statistik

Buksan

---

Nakaraang Pagsara

---

52 Linggo Mataas/Mababa

--- – ---

Market Cap

25565874176

Natitirang Pagbabahagi

239740000

Petsa ng Mga Kita (Susunod)

0000-00-00

Pambayad si dividend

2022-06-17

Araw ng Pag-alis ng Karapatan sa Dividend

2022-06-02

Inaasahang Taunang Rate ng Dividend

0

Inaasahang Taunang Dividend Yield

0

EPS

-2.03

Alamin ang Higit Pa Tungkol sa Instrumentong ito

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

Mga kaugnay na instrumento

view_all_instruments

Mga pinakabagong balita

Manatiling updated sa mga pinakabagong balitang pinansyal mula sa buong mundo.

Miyerkules, 6 Nobyembre 2024

U.S. presidential election market volatility drives Bitcoin prices to reach a historic high

Stock market rally

Martes, 5 Nobyembre 2024

US Election Results Trigger Stock Gains Across Europe, Asia, and US

US Election Trump's victory

Martes, 5 Nobyembre 2024

Trump Victory Spurs Market Gains and Economic Shift Expectations

Martes, 5 Nobyembre 2024

US election: bitcoin price (BTC) surged to new record as Trump leading ahead

Martes, 5 Nobyembre 2024

Stock Market Today: Wall Street Rallies on Election Day Amid Strong Economic Outlook

US Election 2024 Trump

Martes, 5 Nobyembre 2024

Early Election Results Shift Markets as Trump’s Chances Rise

Lunes, 4 Nobyembre 2024

Stock Market Today: S&P 500 Declines as Investors Brace for US Election

Lunes, 4 Nobyembre 2024

US election: What will happen to tesla stock if Trump wins?

Trustpilot
Live Chat